2. Search Result
Search Result
Results for "

Plasmodium falciparum parasite

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

1

Peptides

6

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145912
    RYL-552S

    		Parasite Infection Inflammation/Immunology
    RYL-552S kills drug-resistant strains of Plasmodium falciparum. RYL-552S can efficiently kill asexual blood-stage parasites in vitro .
    RYL-552S
  • HY-103397
    Nanaomycin A
    3 Publications Verification

    		 Antibiotic DNA Methyltransferase Parasite Infection Cancer
    Nanaomycin A is the first selective DNMT3B inhibitor with an IC50 of 500 nM. Nanaomycin A, a quinone antibiotics, reactivates silenced tumor suppressor genes in human cancer cells . Nanaomycin A inhibits in vitro growth of the human malaria parasite Plasmodium falciparum with an IC80 value of 33.1 nM .
    Nanaomycin A
  • HY-117015
    Purfalcamine

    		Parasite Infection
    Purfalcamine is an orally active, selective Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) inhibitor with an IC50 of 17 nM and an EC50 of 230 nM. Purfalcamine has antimalarial activity and causes malaria parasites developmental arrest at the schizont stage .
    Purfalcamine
  • HY-N9320
    13,21-Dihydroeurycomanone

    		Parasite Infection
    13,21-Dihydroeurycomanone, a natural compound isolated from Eurycoma longifolia root, possesses anti-parasite activity for Plasmodium falciparum and Toxoplasma gondii .
    13,21-Dihydroeurycomanone
  • HY-145327
    Antimalarial agent 7

    		Na+/K+ ATPase Parasite Infection
    Antimalarial agent 7 is a potent inhibitor of PfATP4. PfATP4 is an essential ion pump on the parasite surface. Antimalarial agent 7 has the potential for the research of human malaria parasite, Plasmodium falciparum .
    Antimalarial agent 7
  • HY-103397R
    Nanaomycin A (Standard)

    		Antibiotic DNA Methyltransferase Parasite Infection Cancer
    Nanaomycin A (Standard) is the analytical standard of Nanaomycin A. This product is intended for research and analytical applications. Nanaomycin A is the first selective DNMT3B inhibitor with an IC50 of 500 nM. Nanaomycin A, a quinone antibiotics, reactivates silenced tumor suppressor genes in human cancer cells[1]. Nanaomycin A inhibits in vitro growth of the human malaria parasite Plasmodium falciparum with an IC80 value of 33.1 nM[2].
    Nanaomycin A (Standard)
  • HY-N10928
    Lettowienolide

    		Parasite Infection
    Lettowienolide, a geranylbenzoquinonoid, exhibits mild in vitro activity against the Plasmodium falciparum malaria parasite (IC50~20 μg/mL) .
    Lettowienolide
  • HY-N12538
    trans-Cinnamic anhydride

    		Parasite Infection
    trans-Cinnamic anhydride is a Parasite inhibitor tnat can be isolated from Cinnamomum zeylanicum and exhibits moderate activity against Plasmodium falciparum .
    trans-Cinnamic anhydride
  • HY-N8513
    Brevicompanine B

    		Parasite Infection
    Brevicompanine B, a diketopiperazine alkaloid, is an antiplasmodial agent. Brevicompanine B is active against the malaria parasite Plasmodium falciparum 3D7 IC50 of 35 mg/mL .
    Brevicompanine B
  • HY-163727
    MMV1557817

    		Parasite Infection
    MMV1557817 is an orally active and potent antimalarial compound. MMV1557817 is a selective, nanomolar inhibitor of both Plasmodium falciparum and Plasmodium vivax aminopeptidases M1 and M17, leading to inhibition of end-stage hemoglobin digestion in asexual parasites .
    MMV1557817
  • HY-12912
    KDU691

    		PI4K Parasite Infection
    KDU691, an imidazopyrazine with potent anti-parasitic activity against blood stage schizonts, gametocytes and liver stages, is a Plasmodium PI4K inhibitor. KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites .
    KDU691
  • HY-172131
    Emoquine-1

    		Parasite Infection
    Emoquine-1 is an orally active and potent antimalarial drug. Emoquine-1 is efficient against multidrug-resistant Plasmodium parasites, including the Artemisinin-resistant quiescent stage. Emoquine-1 is active against proliferative P. falciparum with IC50 values of 20-55 nM. Emoquine-1 is a candidate to fight Plasmodium parasites resistant to artemisinin-based combination therapies (ACTs) with a capacity to eliminate persistent parasites .
    Emoquine-1
  • HY-N10096
    Epoxyazadiradione

    		Parasite Infection
    Epoxyazadiradione is a limonoid purified from neem (Azadirachta indica) fruits. Epoxyazadiradione inhibits the tautomerase activity of MIF of both human (huMIF) and malaria parasites (Plasmodium falciparum (PfMIF) and Plasmodium yoelii (PyMIF)) non-competitively in a reversible fashion (Ki, 2.11-5.23 μM). Epoxyazadiradione has the potential against proinflammatory reactions induced by MIF of both malaria parasites and human .
    Epoxyazadiradione
  • HY-B0529A
    Azlocillin sodium salt

    Sodium azlocillin

    		 Bacterial Parasite Antibiotic Infection
    Azlocillin sodium salt (Sodium azlocillin), a semisynthetic penicillin, is a broad spectrum β-lactam antibiotic. Azlocillin sodium salt shows antipseudomonal activity, and also potent against the malarial parasite Plasmodium falciparum .
    Azlocillin sodium salt
  • HY-117897
    CK-2-68

    		Parasite Infection
    CK-2-68 is an inhibitor for complex III in protozoan mitochondrial respiratory chain, by targeting the alternative NADH dehydrogenase (NDH2) of the malarial parasite Plasmodium. CK-2-68 exhibits antimalaria efficacy, that inhibits Plasmodium falciparum infected erythrocytes with an IC50 of 40 nM .
    CK-2-68
  • HY-132171A
    DSM705 hydrochloride

    		Dihydroorotate Dehydrogenase Parasite Infection
    DSM705 hydrochloride, an orally active antimalarial compound, is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM705 hydrochloride exhibits nanomolar potency against Plasmodium DHODH and Plasmodium parasites (IC50=95, 52 nM for P. falciparum and P. vivax DHODH, respectively), with no inhibition of mammalian DHODHs .
    DSM705 hydrochloride
  • HY-B0529AR
    Azlocillin (sodium salt) (Standard)

    		Bacterial Parasite Antibiotic Infection
    Azlocillin (sodium salt) (Standard) is the analytical standard of Azlocillin (sodium salt). This product is intended for research and analytical applications. Azlocillin sodium salt (Sodium azlocillin), a semisynthetic penicillin, is a broad spectrum β-lactam antibiotic. Azlocillin sodium salt shows antipseudomonal activity, and also potent against the malarial parasite Plasmodium falciparum .
    Azlocillin (sodium salt) (Standard)
  • HY-P5344
    Dabcyl-LNKRLLHETQ-Edans

    Fluorigenic PEXEL peptide

    		 Parasite Others
    Dabcyl-LNKRLLHETQ-Edans (Fluorigenic PEXEL peptide) is a biological active peptide. (This FRET substrate peptide for Plasmepsin V (PMV) is derived from the conserved Plasmodium Export Element (PEXEL) motif of Histidine-Rich Protein II (HRPII). PMV is an ER aspartic protease that recognizes and cleaves the RXL sequence within the PEXEL motif of proteins exported by human malaria parasite Plasmodium falciparum, allowing them to translocate into host erythrocytes.)
    Dabcyl-LNKRLLHETQ-Edans
  • HY-148315
    GLUT1-IN-2

    		GLUT Infection
    GLUT1-IN-2 (compound 17) is a GLUT1 inhibitor with an IC50 value of 12 μM. GLUT1-IN-2 shows inhibitory effect to Plasmodium falciparum hexose transporter PfHT with an IC50 value of 13 μM. GLUT1-IN-2 can be used for the research of infection .
    GLUT1-IN-2
  • HY-159479
    PfSUB1-IN-1

    		Parasite Infection
    PfSUB1-IN-1 (compound 4c) is a plasmodium falciparum subtilisin-like serine protease 1 (PfSUB1) Inhibitor (IC50: 15 nM). PfSUB1 is an antimalarial target. PfSUB1-IN-1 inhibits the growth of a genetically modified P. falciparum line expressing reduced levels of PfSUB1 13-fold more efficiently compared to a wild-type parasite line .
    PfSUB1-IN-1
  • HY-B0148
    Risedronic acid
    1 Publications Verification

    Risedronate

    		 Parasite Apoptosis Infection Metabolic Disease Cancer
    Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC50 of 20.3 μM) .
    Risedronic acid
  • HY-148178
    MMV688533

    		Parasite Infection
    MMV688533 is an antimalarial agent with rapid anti-plasmodial activity and effective single-dose activity against Plasmodium falciparum infection in humanized mouse models. MMV688533 can inhibit the activity of asexual blood stage parasites with an IC50 value of 1.3 nM. MMV688533 exhibits excellent pharmacokinetic properties and safety .
    MMV688533
  • HY-111817
    ACT-451840

    		Parasite Infection
    ACT-451840 is an orally active, potent and low-toxicity compound, showing activity against sensitive and resistant plasmodium falciparum strains. ACT-451840 targets all asexual blood stages of the parasite, has a rapid onset of action. ACT-451840 behaves in a way similar to artemisinin derivatives, with very rapid onset of action and elimination of parasite. ACT-451840 can be used for the research of malarial .
    ACT-451840
  • HY-116535A
    DL-threo-PPMP hydrochloride

    		Parasite Infection
    DL-threo-PPMP hydrochloride is an inhibitor of sphingosine synthetase in Plasmodium falciparum. DL-threo-PPMP hydrochloride inhibits the activity of sphingosine synthetase (sphingosine synthetase) by binding to a substrate that mimics sphingosine. This inhibition leads to a rapid decline in sensitive sphingomyelin synthase (SSS) activity, selectively disrupting the interconnected tubular network of TVM in the cytoplasm of the host cell, and this inhibition also blocks the proliferation of the parasite. DL-threo-PPMP hydrochloride can be used in the study of malaria parasite biology and the search for new antimalarial strategies .
    DL-threo-PPMP hydrochloride
  • HY-159963
    PfCLK3-IN-1

    		Parasite Infection
    PfCLK3-IN-1 (Compound 4) is a covalent inhibitor for Plasmodium falciparum CLK3 (Pf CLK3) under alkaline conditions with an pEC50 of 7.1. PfCLK3-IN-1 reduces mature gametocytes in sexual stage parasites, and prevents transmission. PfCLK3-IN-1 inhibits P. falciparum Dd2-B2 clone with an IC50 of 239.5 nM .
    PfCLK3-IN-1
  • HY-103353
    SID 26681509
    5 Publications Verification

    		 Cathepsin Parasite Infection Cancer
    SID 26681509 is a potent, reversible, competitive, and selective inhibitor of human cathepsin L with an IC50 of 56 nM. SID 26681509 inhibits in vitro propagation of malaria parasite Plasmodium falciparum and inhibits Leishmania major with IC50s of 15.4 μM and 12.5 μM, respectively. SID 26681509 shows no inhibitory activity against cathepsin G .
    SID 26681509
  • HY-129476
    L-Canaline

    		Parasite Endogenous Metabolite Infection Cancer
    L-Canaline is a nonprotein amino acid stored in many leguminous plants. L-Canaline is a cytotoxic metabolite catalyzed by L-canavanine and its arginase. L-Canaline is a potent and irreversible inhibitor of ornithine aminotransferase. L-Canaline inhibits the growth of the malaria parasite Plasmodium falciparum with an IC50 of 297 nM. L-Canaline has anticancer and antiproliferative effects .
    L-Canaline
  • HY-103353A
    SID 26681509 quarterhydrate
    5 Publications Verification

    		 Cathepsin Parasite Infection Cancer
    SID 26681509 quarterhydrate is a potent, reversible, competitive, and selective inhibitor of human cathepsin L with an IC50 of 56 nM. SID 26681509 quarterhydrate inhibits in vitro propagation of malaria parasite Plasmodium falciparum and inhibits Leishmania major with IC50s of 15.4 μM and 12.5 μM, respectively. SID 26681509 quarterhydrate shows no inhibitory activity against cathepsin G .
    SID 26681509 quarterhydrate
  • HY-B0119
    Risedronic acid sodium
    1 Publications Verification

    Risedronate sodium

    		 Parasite Apoptosis Infection Metabolic Disease Cancer
    Risedronic acid (Risedronate) sodium, a bisphosphonate, is a potent anti-resorption agent that inhibits osteoclast-mediated bone resorption and changes the bone metabolism. Risedronic acid sodium suppresses osteoblast differentiation and induced caspase- and isoprenoid depletion-dependent apoptosis. Risedronic acid sodium inhibits blood stages of Plasmodium falciparum (IC50 of 20.3 μM). Risedronic acid sodium inhibits the transfer of the farnesyl pyrophosphate group to parasite proteins .
    Risedronic acid sodium
  • HY-153612
    MMV009085

    		GLUT Parasite Infection Inflammation/Immunology
    MMV009085 is a potent PfHT1 (Plasmodium falciparum hexose transporter)-specific inhibitor and a potential anti-malarial agent . MMV009085 is also a human glucose transporter inhibitor, it has high potency in inhibiting both glucose uptake (IC50: 2.6 μM in glucose uptake assay) and growth of the parasites (EC50: 1.23±0.04 μM against 3D7) .
    MMV009085
  • HY-149960
    Antiparasitic agent-17

    		Parasite Infection
    Antiparasitic agent-17 (compound 5u) is an orally active antiparasitic agent. Antiparasitic agent-17 inhibits Chloroquine sensitive (Pf3D7) and Chloroquine resistant (PfK1) strain with IC50s of 0.96 μM and 1.67 μM, respectively .
    Antiparasitic agent-17
  • HY-B0148R
    Risedronic acid (Standard)

    Risedronate (Standard)

    		 Parasite Apoptosis Infection Metabolic Disease Cancer
    Risedronic acid (Standard) (Risedronate (Standard)) is the analytical standard of Risedronic acid (HY-B0148). This product is intended for research and analytical applications. Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC50 of 20.3 μM).
    Risedronic acid (Standard)
  • HY-B0148S
    Risedronic acid-d4

    Risedronate-d4

    		 Isotope-Labeled Compounds Parasite Apoptosis Infection Metabolic Disease Cancer
    Risedronic acid-d4 (Risedronate-d4) is the deuterium labeled Risedronic acid (HY-B0148). Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC50 of 20.3 μM) .
    Risedronic acid-d4
  • HY-W078844
    PfDHODH-IN-2

    		Dihydroorotate Dehydrogenase Parasite Infection
    PfDHODH-IN-2, a dihydrothiophenone derivative (Compound 11), is a potent Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor with an IC50 of 1.11 µM. PfDHODH-IN-2 acts as an antimalarial agent and can be used for the research of malaria .
    PfDHODH-IN-2
  • HY-125728
    Micrococcin P1

    		Bacterial Parasite HCV Infection
    Micrococcin P1 is a macrocyclic peptide antibiotic and is a potent hepatitis C virus (HCV) inhibitor with an EC50 range of 0.1-0.5 μM . Micrococcin P1 has in vitro antibacterial activity against Gram-positive bacterial strains. The MIC values of Micrococcin P1 against S. aureus 1974149, E. faecalis 1674621 and S. pyogenes 1744264 are 2 μg/mL, 1 μg/mL and 1 μg/mL, respectively . Micrococcin P1 is also a potent inhibitor of the malaria parasite Plasmodium falciparum .
    Micrococcin P1
  • HY-126323A
    TCMDC-135051 TFA

    		Parasite Infection
    TCMDC-135051 TFA is a highly selective and potent protein kinase PfCLK3 inhibitor with low off-target toxicity. TCMDC-135051 TFA prevents trophozoite-to-schizont transition, disrupts transcription and reduces transmission to the mosquito vector. TCMDC-135051 TFA has antiparasiticidal activity (EC50=320 nM) .
    TCMDC-135051 TFA
  • HY-126323
    TCMDC-135051

    		Parasite Infection
    TCMDC-135051 is a highly selective and potent protein kinase PfCLK3 inhibitor with low off-target toxicity. TCMDC-135051 prevents trophozoite-to-schizont transition, disrupts transcription and reduces transmission to the mosquito vector. TCMDC-135051 has antiparasiticidal activity (EC50=320 nM) .
    TCMDC-135051
  • HY-126323B
    TCMDC-135051 hydrochloride

    		Parasite Infection
    TCMDC-135051 hydrochloride is a highly selective and potent protein kinase PfCLK3 inhibitor with low off-target toxicity. TCMDC-135051 hydrochloride prevents trophozoite-to-schizont transition, disrupts transcription and reduces transmission to the mosquito vector. TCMDC-135051 hydrochloride has antiparasiticidal activity (EC50=320 nM) .
    TCMDC-135051 hydrochloride
  • HY-169194
    Antimalarial agent 44

    		Parasite Infection
    Antimalarial agent 44 (Compound 3) is an antimalarial agent against parasite. Antimalarial agent 44 has a good permeability across MDCK-MDR1 cell monolayers and a high clearance by mouse liver microsomes .
    Antimalarial agent 44